|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.85 SEK | -0.71% |
|
+0.72% | -46.44% |
| Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
| Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Genovis AB (publ.) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 158.23 million compared to SEK 102.39 million a year ago. Revenue was SEK 164.95 million compared to SEK 110.13 million a year ago.
Net income was SEK 61.5 million compared to SEK 11.19 million a year ago. Basic earnings per share from continuing operations was SEK 0.94 compared to SEK 0.17 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -46.44% | 168M | |
| +0.70% | 12.95B | |
| -7.57% | 7.84B | |
| +1.52% | 5.5B | |
| +0.93% | 4.61B | |
| +8.48% | 4.61B | |
| -49.25% | 3.4B | |
| +9.21% | 2.66B | |
| -14.59% | 2.08B | |
| +3.45% | 1.79B |
GENOVIS AB 
